Krish S Krishnan

KRYS CEO Krishnan sold 25,000 shares for $7.7M (avg $308.12) via scheduled 10b5-1 plan on 2026-06-04

Krish S Krishnan, President and CEO of Krystal Biotech, executed 11 separate sales totaling 25,000 shares for $7,702,983.82 on 2026-06-04, reducing his holdings from 1,475,253 shares to 1,450,253 shares (a -1.7% net change). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, meaning it was scheduled rather than discretionary. The blended average sale price was $308.12, slightly above the current price of $301.00. The company's fundamentals show strong growth (annual revenue growth of +33.9%) and profitability (net income of $55,932,000.00 on revenue of $116,357,000.00 in the latest quarter), though the P/E ratio of 39.45 reflects investor expectations. Given the scheduled nature of the transaction under a 10b5-1 plan, this sale does not convey timing-dependent signals; it represents predetermined portfolio activity that proceeded regardless of current market conditions.

KRYS CEO Krishnan Krish S sold 25,000 shares (25.0K shares) for $6,579,164.35 ($6.6M) on 2026-03-04, reducing stake to 1.48M shares.

CEO Krishnan Krish S executed 10 separate sales totaling 25,000 shares for $6,579,164.35 across a narrow range ($257.31–$266.56), a blended average of $263.17 on a single trading day, reducing his holdings by 1.7%. The current stock price of $253.69 sits 13.1% below the 52-week high, and the insider's five prior trades at KRYS in December 2025 posted 90-day positive returns (ranging 19.3%–23.7%), indicating his recent sales at this ticker have not preceded declines. Against KRYS fundamentals of 33.9% annual revenue growth, $79.4M net income on $97.8M quarterly revenue, and a 23.58 P/E, the transaction reflects a large single-day liquidation by the top executive while the stock remains well below its recent peak—a material move warranting investor attention for signal clarity, particularly given the company's strong revenue growth trajectory.

CEO Krishnan sells 50,000 shares for $11.0M at $220.15 avg (near 52-week high of $234.13)

Krishnan Krish S, President and CEO of Krystal Biotech, executed 16 separate sales totaling 50,000 shares for $11.0M on 2025-12-04, reducing his holdings by 3.4% to 1,413,711 shares. The blended average price of $220.15 is very close to the current price of $234.13 and the 52-week high of $234.13, indicating the sale occurred near peak valuation. Over his cross-ticker track record, Krishnan's prior 20 sells posted an average 90-day return of +11.8%, with only 25.00% of sales proving well-timed (stock declining after sale); however, at KRYS specifically, none of his 5 prior sells were well-timed, all posting positive 90-day returns as the stock rallied after each sale. This sale stands out in both volume and timing: it is materially larger than his prior transactions at KRYS and occurs as the stock has appreciated 17.1% in the past 30 days and 55.8% in the past 90 days, during a period of exceptional company growth (473% annual revenue growth, $97.8M latest-quarter revenue, $79.4M net income) but elevated valuation (P/E of 34.13).

CEO Krishnan Krish S sold 35,873 shares for $5,395,000.82 across 9 transactions from July 14-16, 2025; retains 1,438,711 shares post-sale.

Krishnan Krish S (President and CEO) executed 9 separate sales totaling 35,873 shares for $5,395,000.82 (blended average $150.39 per share) over three trading days ending July 16, 2025, reducing his shareholding by 2.4% to 1,438,711 shares. The timing is notable: the sales occurred after the stock had already declined 29.8% from its 52-week high of $213.66 while recently gaining 12.8% over the prior 30 days, and just days after five prior sales by the same insider on July 9-10. Across his entire cross-ticker transaction history, his 20 prior sales show a well-timed rate of 71.43% (with average 90-day returns of -13.3%), though his prior trades at KRYS have no measurable outcomes yet. The rapid succession of sales in mid-July warrants investor attention given the insider's otherwise disciplined track record and the scale of recent disposal activity.

KRYS CEO Krishnan sells 14,127 shares for $2.1M in 6 transactions; prior 5 KRYS sales all well-timed by 90-day mark

Krishnan Krish S, President and CEO of Krystal Biotech, executed 6 separate sales totaling 14,127 shares (14.1K shares) for $2,122,834.96 ($2.1M) at a blended average price of $150.27 on July 9–10, 2025, reducing holdings by 1.0% to 1,456,711 shares (1.46M shares). The current stock price is $148.17, down 30.6% from the 52-week high of $213.66, yet the insider's transaction prices ($150.07–$151.39) sit above current market. This sale pattern mirrors a strong historical precedent: across his 5 prior trades at KRYS, all were well-timed at the 90-day mark, with 90-day returns ranging from -20.6% to -21.9%, indicating the stock declined after each insider sale. The timing signal is particularly notable given the company's robust fundamentals—annual revenue growth of 473.0%, net income of $35,733,000.00, and a P/E of 34.54—suggesting the CEO's discretionary sale captures a local peak despite strong underlying earnings. Investors should note that while the position remains substantial at 1.46M shares, the consistent 90-day decline pattern in prior KRYS insider sales may warrant monitoring for near-term price action.

CEO Krishnan sells 50,000 shares (3.3% of holdings) for $8.9M at blended avg $177.79; stock +18.3% (30d), down 17.0% from 52-week high.

Krishnan Krish S, President and CEO of Krystal Biotech, executed 10 separate sales totaling 50,000 shares for $8,889,524.57 on 2025-03-13 at prices ranging from $175.83 to $179.57, with a blended average price of $177.79. This reduces his post-transaction holdings to 1,463,711 shares, a net decrease of 3.3% from his pre-transaction position. The stock is currently at $177.37, up 18.3% over 30 days but remains 17.0% below its 52-week high of $213.66. His prior sales at Krystal Biotech (5 trades in December 2024) averaged negative 30-day returns (-8.3% mean) but positive 90-day returns (+6.4% mean), with none of those trades being well-timed at the 90-day horizon (all returned positive, meaning the stock rose after he sold). Cross-ticker, his broader track record shows 20 prior sells with a 15.00% well-timed rate at 90 days, substantially below median performance for consistently profitable sell-timing. The stock trades at a P/E of 39.15 on quarterly revenue of $83.8M (up 473.0% year-over-year) and net income of $27.2M, reflecting a high-growth biotech profile where recent momentum may be pulling the stock into overbought territory relative to historical range.

KRYS CEO Krishnan sold 50,000 shares for $8.2M on 2024-12-13; stock down 23.4% from 52-week high, all 5 prior KRYS sales well-timed at 90d.

Krishnan Krish S, President and CEO, executed 17 separate sales totaling 50,000 shares for $8,240,023.06 at blended average price $164.80 on 2024-12-13, reducing holdings by 3.3% to 1,475,882 shares. The stock is trading at $163.64, down 23.4% from its 52-week high of $213.66 and down 11.2% over the past 30 days. Notably, all 5 of Krishnan's prior sales at KRYS (executed 2024-09-12) proved well-timed, with the stock declining 4.2% to 11.3% in the 90 days following each sale. His cross-ticker track record shows a 75.00% well-timed rate across 20 prior sells. The large multi-tranche sale following months of stock decline, combined with Krishnan's historical pattern of well-timed exits at this ticker, warrants attention to whether similar post-sale weakness may emerge over the next 90 days.

KRYS CEO Krishnan sells 50,000 shares ($9.9M) on 2024-09-12 at blended avg $197.77

Krishnan Krish S, President and CEO of Krystal Biotech, executed 15 separate sales totaling 50,000 shares for $9,888,276.35 on 2024-09-12, reducing holdings by 3.2% to 1,500,882 shares post-transaction. The stock traded in a range of $195.16 to $201.81 across the transactions, with a blended average price of $197.77, versus a current price of $201.58. His prior 5 open-market sales at KRYS (all on 2024-06-11) showed 30-day returns of +11.4% to +15.8%, but notably none were well-timed at the 90-day mark—the stock rose following each prior sale, suggesting the executive sold before continued momentum. The magnitude ($9.9M across a $5.8B market cap) and the multi-tranche execution pattern warrant monitoring to determine whether this represents a one-time liquidity need or a broader shift in conviction at a company posting net income of $15,568,000.00 on revenue of $70,284,000.00.